Skip to content

BioLife Solutions

US · BLFS #2844 by market cap Listed 1970
0.00 0.00 0.00%
Snapshot may be outdated; check the quote time before use. · 2026-10-21 19:54

Price chart

39.2219.7138.612026-04-082026-10-07
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BLFS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +42.5% on average (3-month/1-year).
  • Short interest has risen to 8.2% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall C-
ValuationGrowthProfitMomentumHealthAnalyst
Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 32.7x Better than 19%
Forward P/E 145.1x Better than 2%
Price / Sales 17.7x Better than 6%
P/E vs own 5-yr range 92nd pctl Better than 11%
Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 8.1% Better than 59%
Net income CAGR (3Y) 0.0% Better than 41%
Free cash flow CAGR (3Y) 63.4% Better than 88%
Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 64.6% Better than 79%
Operating margin -17.3% Better than 13%
Net margin -4.8% Better than 20%
Return on equity -1.3% Better than 26%
Return on invested capital -1.2% Better than 27%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 4.1% Better than 82%
6-month return 61.2% Better than 97%
12-month return (ex latest month) 45.5% Better than 81%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.9x Better than 89%
Debt to assets 4.4% Better than 81%
Interest coverage -638.6x Better than 2%
Free cash flow / net income 75.4% Better than 24%
Analyst View F

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 0.0% Better than 0%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -0.62%
1M +9.53%
3M +38.24%
6M +101.83%
YTD +59.68%
1Y +46.81%
3Y +185.16%
5Y -5.37%

Key statistics

Price & volume

Prev close
0.00
Open
0.00
Day range
0.00 - 0.00
Avg price
0.00
Volume
0
Turnover
0
Amplitude
0.00%
52-week range
0.00 - 0.00

Valuation

P/E
-386.10
P/E (TTM)
32.72
P/B
4.50
EPS
-0.10
Net profit
-4.89M
Net assets
420.01M

Share structure

Market cap
1.89B
Float cap
1.55B
Shares out
48.92M
Float shares
40.14M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01

Trading activity

Net capital flow main funds, last 45 sessions

-21.36M net over the window

Short interest

Shares short
4.00M
As of
2026-09-30

Frequently asked questions

What is the current stock price of BioLife Solutions (BLFS)?

BioLife Solutions last traded at 0.00. This page shows a periodic quote snapshot. Check the displayed quote time.

What is BioLife Solutions's market cap?

About 1.89B.

What is the P/E ratio of BioLife Solutions?

The trailing twelve-month P/E is 32.72. The Valuation tab shows it against the stock's own five-year range.

Does BioLife Solutions pay a dividend?

BioLife Solutions does not currently pay a regular dividend.

Is BioLife Solutions a buy according to analysts?

The consensus of 6 analysts is a Hold rating, with an average 12-month price target of 31.00. This is not investment advice.

What is BioLife Solutions's StockVane Quant Rating?

The StockVane Momentum strategy currently rates BioLife Solutions a B (Buy). Twelve-month momentum in the top 21% of the universe, above its 200-day average. Not investment advice.

Quote time 2026-10-21 19:54:59 · For reference only, not investment advice and not tailored to your situation.

BioLife Solutions discussion 0 comments

Add a comment